SARS CoV-2 Spike Glycoprotein UK variant Positive Control for STJ506294 peptide (UK variant) (STJ506297)
SPECIFICATIONS
General Information
| Short Description | SARS CoV-2 Spike Glycoprotein UK variant Positive Control for STJ506294 is synthetically produced from the 650-800 sequence about the UK variant and is suitable for use in western blot applications. |
| Applications | WB |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is |
| Storage Instruction | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Immunogen Region | 650-800 |
| Specificity | This is positive control is recommended for use in combination with SARS CoV-2 Spike Glycoprotein UK variant antibody STJ506294. |